Alumis Inc. (ALMS)
Develops experimental drugs to treat autoimmune and inflammatory diseases like psoriasis and lupus.
$26.94-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+552.3%
The outlook
Analysts rate ALMS a strong buy, and the stock is trading well above its medium and long-term moving averages. At 84% of the way up its 52-week range, it's near recent highs, with the average analyst target sitting roughly 49% above the current price.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 10 analysts
Price trendAbove its 50- & 200-day averages
52-week range84% of the way from its 52-week low to high
Price targetAvg target +49% vs current price
Analyst price target
~12-month · 10 analysts$40.10average target+48.8% vs now
Now $26.94
Low $25.00High $55.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$3.43B
52-wk high
$31.35
52-wk low
$3.76
50-day avg
$24.56
200-day avg
$19.51
Trailing P/E
—